CLDN18.2 POSITIVE
Clinical trials for CLDN18.2 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CLDN18.2 POSITIVE trials appear
Sign up with your email to follow new studies for CLDN18.2 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to wipe out stomach cancer before surgery
Disease control Recruiting nowThis study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants w…
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 23, 2026 22:16 UTC
-
New drug combo targets Hard-to-Treat cancers in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 study tests a new drug called IBI343 combined with two standard chemotherapies (gemcitabine and nab-paclitaxel) in about 389 people with advanced stomach or pancreatic cancers that have a specific protein (CLDN18.2). The main goals are to see if the combination shrin…
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC